Cite
HARVARD Citation
Denkert, C. et al. (n.d.). 2022-RA-1492-ESGO Homologous recombination deficiency (HRD): a new ovarian cancer biomarker – validation of decentralized genomic profiling, with a focus on genomic large rearrangements (LRs). International journal of gynecological cancer. p. A343. [Online].